Next Article in Journal
Genome-Wide Identification and Expression Analysis of Calmodulin and Calmodulin-like Genes, Revealing CaM3 and CML13 Participating in Drought Stress in Phoebe bournei
Next Article in Special Issue
Sodium Butyrate Inhibits the Expression of Thymidylate Synthase and Induces Cell Death in Colorectal Cancer Cells
Previous Article in Journal
Comprehensive Analysis of Highbush Blueberry Plants Propagated In Vitro and Conventionally
Previous Article in Special Issue
Downregulation of γ-Catenin by miR-195-5p Inhibits Colon Cancer Progression, Regulating Desmosome Function
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 1
10.3390/ijms25010543
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review

by
Matthew J. Hadfield
1,
Kathryn DeCarli
1,
Kinan Bash
2,
Grace Sun
1 and
Khaldoun Almhanna
1,*
1
Division of Hematology/Oncology, Department of Medicine, The Warren Alpert School of Medicine of Brown University, Providence, RI 02806, USA
2
Department of Graduate Studies, University of New England, Biddeford, ME 04005, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(1), 543; https://doi.org/10.3390/ijms25010543
Submission received: 2 October 2023 / Revised: 21 December 2023 / Accepted: 22 December 2023 / Published: 30 December 2023
(This article belongs to the Special Issue Recent Advances in Gastrointestinal Cancer)
Browse Figure
Review Reports Versions Notes

Abstract

:
Cholangiocarcinoma is a malignancy of the bile ducts that is often associated with late diagnosis, poor overall survival, and limited treatment options. The standard of care therapy for cholangiocarcinoma has been cytotoxic chemotherapy with modest improvements in overall survival with the addition of immune checkpoint inhibitors. The discovery of actionable mutations has led to the advent of targeted therapies against FGFR and IDH-1, which has expanded the treatment landscape for this patient population. Significant efforts have been made in the pre-clinical space to explore novel immunotherapeutic approaches, as well as antibody–drug conjugates. This review provides an overview of the current landscape of treatment options, as well as promising future therapeutic targets.

1. Introduction

1.1. Cholangiocarcinoma Epidemiology

Cholangiocarcinoma, predominantly adenocarcinomas, encompasses gallbladder cancers, ampullary carcinomas, and intrahepatic and extrahepatic cholangiocarcinoma. Tumors of the biliary tract are usually classified based on their anatomical origin, intra- or extrahepatic. While these cancers are distinct and heterogenous, they are often studied together due to low incidence, with approximately 12,000 cases occurring in the United States per year [1]. Gallbladder cancer is more common among women and patients with prior cholelithiasis, calcification of the gallbladder wall, pancreaticobiliary maljunction, or gallbladder polyps. Additionally, chronic inflammation is a common risk factor for both gallbladder cancer and cholangiocarcinoma, which is associated with primary sclerosing cholangitis, cirrhosis, infectious hepatitis, and recurrent bile duct calculi. In East Asia, chronic inflammation from liver fluke infections contributes to an increased incidence of high-risk disease [2]. These malignancies are often diagnosed at a late stage. Prognosis is poor, with median survival in gallbladder cancer ranging from 5.8 months for metastatic disease to 12.9 months for earlier-stage disease [3]. The 5-year survival rate for resectable cholangiocarcinoma ranges from 16% to 52%, with a high risk of disease recurrence [4].

1.2. Standard Treatment

Only about one-third of patients with cholangiocarcinoma and malignancies of the gallbladder present with localized disease [2]. The standard curative treatment for early-stage disease is surgical resection, with or without neoadjuvant platinum doublet or fluoropyrimidine-based chemotherapy. While the programmed death ligand-1 (PD-1) inhibitor durvalumab was recently approved for the treatment of metastatic disease, its role has yet to be established in the neoadjuvant setting. Select patients with unresectable disease may be considered for liver transplant; however, the criteria for transplant in this patient population are not well established. The role of adjuvant chemotherapy has not been robustly studied due to low incidence, but there are data to support prolonged survival in patients who receive adjuvant chemotherapy or chemoradiation [5,6,7,8].
Most patients present with unresectable or metastatic disease and may be offered clinical trials, best supportive care, or systemic therapy. Gemcitabine plus cisplatin has been considered the standard of care first-line systemic therapy since 2010, based on the results of the phase III ABC-02 study [9]. In 2022, the phase III TOPAZ-1 trial demonstrated survival benefit with the addition of durvalumab to this regimen, leading to the adoption of concurrent chemoimmunotherapy as the new standard of care [10]. Additional accepted systemic therapies may include fluoropyrimidine-based chemoradiation, other gemcitabine-based chemotherapy regimens, or targeted treatments selected based on tumor characteristics and molecular profiling. Unfortunately, the overall survival rate for metastatic disease remains less than one year, highlighting a need for advances in targeted therapy and additional therapeutic combinations to improve survival. Frequently, the treatment of biliary tumors can be complicated by biliary obstruction and liver dysfunction. These complications limit treatment options, making this a challenging patient population to treat.

2. Molecular Targets

2.1. Overview

Based on a recently published genomic analysis, cholangiocarcinoma has proven to be a very heterogenous disease depending on tumor location [11]. This has led to the identification of genomic patterns that correlate with both disease prognosis and potential therapeutic targets (Figure 1). Over 30% of biliary tract malignancies, including cholangiocarcinoma, harbor an actionable mutation with druggable targets [12]. Targeted agents have played an increasing role in the treatment of multiple solid tumor malignancies with the discovery of more actionable mutations, and the utilization of these agents is evolving in the treatment of cholangiocarcinoma. Molecular testing of all unresectable cholangiocarcinoma is now the recommended standard of care to inform treatment decisions and determine eligibility for clinical trial enrollment. In the last several years, several new agents have demonstrated clinical activity in the treatment of cholangiocarcinoma. The benefits, however, have been modest. In this article, we review the most common targetable molecular alterations that are now part of the standard of care for treatment. We also cover the evolving treatment landscape for biliary tract cancers, including novel immune checkpoint inhibitors, adoptive cellular therapies, and drugs targeting the tumor microenvironment and cellular metabolism and the role they will play in the future treatment of hepatobiliary malignancies. Table 1 summarizes recent and ongoing trials of targeted agents in hepatobiliary cancers.

2.2. BRAF V600E

B-Raf proto-oncogene, serine/threonine kinase (BRAF), is a serine/threonine kinase signaling pathway that is one of the most mutated pathways in solid tumors, including biliary cancers. BRAF V600E mutations are seen in approximately 5% of biliary cancers [13]. Treatment response with single-agent BRAF inhibition is often limited due to acquired resistance mutations in the MAPK pathway. The combination of BRAF and MEK inhibitors has been shown to provide more durable responses and received tissue-agnostic FDA approval in 2022 [14]. The combination therapy of the BRAF inhibitor, dabrafenib, and the MEK inhibitor, trametinib, has been studied in BRAF V600E-mutated cholangiocarcinoma. This regimen showed clinical activity among patients with metastatic BRAF V600E-mutated biliary tract cancers in a phase II clinical trial of 43 patients, with an ORR of 46.5% [13]. Dabrafenib plus trametinib combination therapy is now FDA-approved as a subsequent line treatment option for this patient population. Several ongoing trials are now testing different combinations of the above drugs in patients with BRAF mutations, including cholangiocarcinoma.

2.3. EGFR

Epidermal growth factor receptor (EGFR) is the binding membrane receptor for the epidermal growth factor family of proteins. These proteins play a role in regulating cellular proliferation, angiogenesis, and apoptosis [15]. Activating EGFR mutations occur across solid tumors and can be present in up to 15% of hepatobiliary malignancies [2]. The utilization of EGFR-targeting tyrosine kinase inhibitors (TKIs) has been evaluated in small phase II studies of patients with cholangiocarcinoma. Panitumumab, an anti-EGFR monoclonal antibody, demonstrated anti-tumor activity and tolerable safety profile in combination with gemcitabine and irinotecan in a phase II trial of patients with unresectable cholangiocarcinoma [16]. An additional phase II study evaluated the EGFR targeting TKI, Erlotinib, in 42 patients with EGFR-mutated advanced biliary cancer. The study demonstrated that 17% of patients were progression-free at 6 months of 36 evaluable patients [17]. Despite initial promising results from early studies of cetuximab and erlotinib, these have not been born out in subsequent trials [18,19]. The clinical benefit of targeting EGFR in biliary tract malignancies has been less significant than other solid tumors with exceptional responses to these TKIs, such as EGFR-mutated non-small cell lung cancer. The difference in responses between these tumor types highlights the heterogeneity of responses to targeted therapy and warrants further investigation.

2.4. FGFR

Fibroblast growth factor receptor (FGFR) is a group of tyrosine kinase receptors that have a functional role in cellular proliferation and growth. Mutations within the FGFR family of proteins have been implicated in the pathogenesis of cholangiocarcinoma [20]. FGFR-2 mutations are seen in approximately 14% of intrahepatic cholangiocarcinoma and are more common in intrahepatic than extrahepatic cancers [21]. They are associated with increased intraductal cell proliferation and tumorigenesis [2]. Clinically, FGFR-2 mutations may confer more indolent disease and prolonged survival [22,23]. Tyrosine kinase inhibitors targeting FGFR have shown activity and tolerability in patients with FGFR2-mutated cholangiocarcinoma.
The FGFR1-3 inhibitor pemigatinib demonstrated anti-tumor activity in the single-arm phase II FIGHT-202 trial [24]. Among 107 patients with FGFR-2 mutated metastatic cholangiocarcinoma, the ORR was 35.5%, and disease control was achieved in 80% of patients. Toxicities of pemigatinib include electrolyte derangements, notably hyperphosphatemia, hypophosphatemia, and hyponatremia. Hyperphosphatemia was seen in 60% of patients, with 12% experiencing grade 3 AE. Additional toxicities included arthralgias, stomatitis, abdominal pain, fatigue, retinal detachment, and dry eye. The open-label randomized phase III FIGHT-302 trial is currently underway to study pemigatinib versus gemcitabine plus cisplatin chemotherapy as a first-line treatment option for metastatic cholangiocarcinoma [25].
An additional FGFR1-3 inhibitor, infigratinib, has also shown early activity in the treatment of FGFR2-mutated advanced cholangiocarcinoma. In a phase II trial of 108 patients with FGFR-2 gene fusions or rearrangements who were previously treated with at least one gemcitabine-containing regimen, the ORR was 23% [26]. Toxicities of infigratinib are similar to those of pemigatinib, including electrolyte derangements, stomatitis, dry eye, retinopathy, fatigue, and alopecia. Hyperphosphatemia was seen in 76% of patients, while severe hyponatremia and hypophosphatemia were each seen in 13%.
Most recently, the next-generation FGFR1-4 inhibitor futibatinib has also shown activity and a tolerable safety profile in the treatment of advanced cholangiocarcinoma with FGFR-2 fusions or rearrangements. The open-label phase II FOENIX-CCA2 trial included 103 patients with previously treated disease and demonstrated an ORR of 42% [27]. Grade 3 hyperphosphatemia occurred in 30% of patients with less frequent AEs, including increased aspartate aminotransferase level, stomatitis, and fatigue.
These three oral agents are all FDA-approved as subsequent line treatment options in the treatment of advanced FGFR-2 mutated cholangiocarcinoma after disease progression. They offer similar safety profiles and promising clinical applications. In the above trials, futibatinib was given once daily on a continuous dosing schedule, pemigatinib was given once daily for 14 days of a 21-day cycle, and infigratinib was given once daily for 21 days of a 28-day cycle. These options are convenient for patients who can reliably take medications at home and are now used in subsequent line standard treatment.

2.5. IDH1/IDH2

Isocitrate dehydrogenase (IDH) is an important enzyme for cellular metabolism. Mutations in the genes encoding the metabolic enzymes isocitrate dehydrogenase IDH-1 and -2 are associated with developing premalignant biliary lesions [2]. IDH1/2 mutations are detected in 13–36% of intrahepatic cholangiocarcinoma and <1% of extrahepatic cholangiocarcinoma, with more women harboring IDH-1 mutations than men [2,28,29]. The IDH-1 inhibitor ivosidenib was shown to improve PFS versus placebo (2.7 vs. 1.4 months, p < 0.0001) among 124 patients with metastatic IDH1-mutated cholangiocarcinoma in a phase III trial. Grade 3 adverse events included hyperphosphatemia in 30% of patients, increased aspartate aminotransferase level in 7% of patients, and stomatitis and fatigue each in 6% of patients [24]. Ivosidenib is now FDA-approved as a subsequent line treatment option in this patient population after disease progression. Further clinical trials are currently underway with IDH-1/IDH-2 targeted therapies in patients with hepatobiliary tumors. Olutasidenib, an IDH-1 inhibitor, was previously studied in Acute Myeloid Leukemia and is currently being tested in a phase I/II clinical trial of patients with solid tumors with expansion cohorts, including hepatobiliary cancers [30]. Previous studies have shown that IDH-1/2 mutated cholangiocarcinoma displays increased evidence of DNA damage, making POLY-ADP Ribose Polymerase (PARP) inhibitors a potential therapeutic option [31]. A trial evaluating the PARPi, Olaparib, in patients with IDH-1/2-mutated glioblastoma and cholangiocarcinoma is currently ongoing.

2.6. Her-2/NEU/ERBB2/ERBB3

Human epidermal growth factor receptor 2 (HER-2) is a receptor tyrosine kinase receptor encoded by the ERBB2 gene. Application of the HER-2 gene leads to downstream upregulation of key receptor signaling pathways that contribute to cellular growth and proliferation [32]. HER-2 targeting agents have been deployed across multiple solid tumors, including breast and gastric, with significant clinical benefit and efficacy. Roughly 13% of gallbladder cancers, 18% of extrahepatic cholangiocarcinoma, and 5% of intrahepatic cholangiocarcinoma overexpress HER-2 via ERBB2 or ERBB3 mutations [33,34,35]. A retrospective study of HER-2-directed therapy, including trastuzumab, pertuzumab, or lapatinib, suggested sustained response to these agents among nine patients with HER-2 mutated gallbladder cancer. However, despite a higher incidence of HER-2 mutations in cholangiocarcinoma compared with gallbladder cancers, five patients with HER-2 mutated cholangiocarcinoma showed no response to HER-2-directed therapy in the same study [36].
Nascent prospective data are beginning to inform the use of these agents in hepatobiliary cancers. A 2021 analysis of 39 patients with HER-2 positive metastatic biliary tract cancers who were treated with trastuzumab plus pertuzumab while enrolled in the phase II My Pathway umbrella study found an ORR of 23% [37]. This finding opens the door for a randomized phase III trial examining targeted therapy for patients with HER-2-positive biliary tract cancers. Zanidatamab, an anti-HER2 bispecific antibody, demonstrated anti-tumor activity in a phase I study of 20 patients with metastatic HER2-positive biliary tract cancer whose disease progressed on prior therapy, with an ORR of 40% [38]. This agent was granted breakthrough therapy status by the FDA for this patient population and is being studied in the ongoing phase II HORIZON trial. The antibody–drug conjugate trastuzumab deruxtecan recently demonstrated an ORR of 36.4% in the phase II HERB trial among 22 patients with metastatic HER2-positive biliary tract cancer. Notably, this trial also included eight patients with HER-2 low-expressing tumors with a 12.5% ORR [39]. While there was an increased incidence of interstitial lung disease seen in the trial, including two fatal cases, these results suggest a new role for targeted therapy to improve outcomes in this patient population.

2.7. Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) are a group of antibody drugs that target immune checkpoint proteins, including cytotoxic T-Lymphocyte agent-4 (CTLA-4) and programmed death-1/programmed death-ligand-1 (PD-1/PDL-1.) ICIs have revolutionized the treatment of solid tumor malignancies since the first FDA approval of ipilimumab in 2011 for metastatic melanoma. Microsatellite instability (MSI) refers to regions of repeating DNA that change in length when underlying DNA repairing mismatch repair (MMR) proteins are mutated and do not function correctly [40]. In 2017, the FDA granted accelerated approval to the PD-1 inhibitor, Pembrolizumab, for tissue-agnostic tumors demonstrating MSI-H or MMR deficiency. The rate of MSI-H hepatobiliary cancers ranges from 0 to 60%, depending on the microsatellite markers used for testing [41]. MSI-H gallbladder cancers occur at increased prevalence among patients with a history of chronic cholecystitis; pancreaticobiliary maljunction is associated with a higher prevalence of MSI-H status in both gallbladder and cholangiocarcinoma.
The current standard of care for cholangiocarcinoma is a combination of chemotherapy and immune checkpoint inhibition based on the results of the TOPAZ-1 trial. This was a phase III study that evaluated the combination of gemcitabine and cisplatin combined with either the PD-1 inhibitor Durvalumab or placebo. The study demonstrated 24.9% overall survival at 24 months in the Durvalumab arm vs. 10.4% in the placebo arm.
Additional studies evaluating immune checkpoint inhibitors in hepatobiliary cancers have been explored. Pembrolizumab, a PD-1 inhibitor, has been shown to be effective in the treatment of patients with MSI-H/dMMR tumors, with 22 cholangiocarcinoma patients included in the phase II KEYNOTE-158 study [42]. In the subgroup analysis of patients with MSI-H/dMMR cholangiocarcinoma, pembrolizumab conferred an ORR of 40.9% [42]. TMB-H cholangiocarcinoma also showed a response to pembrolizumab. Pembrolizumab is approved in the second-line treatment of metastatic MSI-H, dMMR, or TMB-H solid tumors, including hepatobiliary cancers [43]. Pembrolizumab also shows promise in combination with Lenvatinib as a subsequent line therapy for patients with advanced hepatobiliary cancer not previously exposed to a checkpoint inhibitor, based on the results of the phase II LEAP-005 study [44].
Nivolumab, also a PD-1 inhibitor, showed an ORR of 22% among 46 patients with advanced hepatobiliary cancer [45]. In this study, all patients who responded to treatment with nivolumab had MMR-proficient tumors. Based on these results, nivolumab is accepted as a subsequent line treatment for patients in this population who have not been previously exposed to a checkpoint inhibitor.

2.8. NTRK

The family of neurotrophic tropomyosin kinase receptors (NTRK) is a transmembrane tyrosine kinase that is integral to neural development through the activation of growth signaling pathways. NTRK protein fusions have been implicated in multiple solid tumor malignancies [46]. NTRK inhibitors Intrectinib and Larotrectinib are accepted as targeted treatment options for patients with metastatic biliary tract cancers harboring NTRK fusion genes, which make up <1% of these cancers. This recommendation is based on umbrella studies of NTRK inhibitors in solid tumors [47,48].

2.9. VEGF

Vascular endothelial growth factor (VEGF) is a potent growth factor that stimulates angiogenesis. VEGF has been shown to promote angiogenesis in tumors, thus contributing to cancer cell growth and proliferation. VEGF targeting agents have been shown to slow growth in other solid tumors [Elebiyo]. VEGF is overexpressed in up to 75% of hepatobiliary malignancies [2]. In a phase II trial, sorafenib, given in combination with gemcitabine, improved survival compared with gemcitabine plus placebo among patients with unresectable biliary tract cancer who developed liver metastases following resection [49]. These findings are not yet supported by phase III studies. Similarly, regorafenib has been shown in phase II studies to have clinical activity and provide modest survival benefit versus placebo in patients with metastatic biliary tract cancer [50,51].

2.10. RET

The RET proto-oncogene is a protein receptor tyrosine kinase that, when constituently activated, can lead to the development of cancer. RET is a rare mutation, occurring in only 1.8% of all solid tumors as either a fusion, amplification, or gene mutation [52]. RET alterations have been shown to occur in only 1.6% of hepatobiliary tract cancers [53]. The only available clinical trial data on RET targeting agents in cholangiocarcinoma is from a phase II study of Selpercatinib, a RET tyrosine kinase inhibitor with highly selective binding. In the study, one patient with biliary tract cancer derived a response and remained in the study at the time of data cutoff [54]. Given the tissue agnostic approval for Selpercatanib, this would be an appropriate choice for a patient with cholangiocarcinoma harboring these genetic aberrations.

2.11. Future Therpatuic Targets

The treatment landscape for cholangiocarcinoma is rapidly evolving, with several novel therapeutic strategies in both pre-clinical and clinical development. Antibody–drug conjugates (ADCs) allow targeting cell surface receptors to deliver cytotoxic payloads and reduce systemic toxicities. Adoptive cellular therapies, including chimeric antibody receptor T-cell (CAR-T) and nature killer cell (NK cell) therapies, aim to harness the immune response beyond only targeting immune checkpoint proteins. The utilization of novel immunotherapies has been deployed to help overcome both primary and acquired resistance to immune checkpoint inhibitors. Additionally, drugs targeting the tumor microenvironment and tumor metabolism are under investigation for the treatment of multiple solid tumors, including those of the biliary tract.

2.12. Antibody–Drug Conjugates

Antibody–drug conjugates (ADCs) are novel drug delivery mechanisms with two primary components: An antibody capable of targeting proteins expressed on the cell surface as well as a ‘payload’ of a cytotoxic chemotherapeutic agent [55]. Several promising cell surface protein targets have been identified that are under pre-clinical investigation for the treatment of cholangiocarcinoma.
Yashima et al. conducted a pre-clinical study evaluating an ADC comprised of an HER-2-targeting antibody in conjunction with a trastuzumab emtansine payload in the CCA cell line. The study demonstrated that cell death was increased in HER-2 overexpressing CCA cells when compared to HER-2 negative cells by IHC GPC-1 is a cell surface proteoglycan receptor that contributes to cellular growth and proliferation by acting as a co-receptor with other pro-growth cellular receptors [55]. GPC-1 overexpression has been demonstrated in up to 47% of CCA tumor specimens [56]. ADCs targeting GPC-1 have been evaluated in pre-clinical CCA cell lines.
Yokota et al. investigated a GPC-1 targeting ADC with the drug payload of monomethyl auristatin F (MMAF), an anti-neoplastic agent that is a component of balantamb mafodotin, that is commonly employed in multiple myeloma [56]. In their study, it was found that this GPC-1 targeting ADC showed significant anti-tumor activity in both in vivo and in vitro models. Additional work demonstrated that GPC-1 knockout mice also had anti-tumor growth activity. Additional work by Zhu et al. established intra-adhesion molecule-1 (ICAM-1) as a highly expressed cell surface marker in CCA cell lines, representing a viable therapeutic target. Additional work demonstrated increased cytotoxicity when an antibody targeting ICAM-1 was conjugated with a cytotoxic payload when tested in both in vivo and in vitro experiments [57].

2.13. Adoptive Cellular Therapies

MUC-1 is a group of epithelial glycoproteins that have gained significant traction as potential anti-neoplastic targets, given their integral functioning in cellular growth and potentiation [58]. Lymphokine-activated killer (LAK) cells are an adoptive cellular therapy consisting of T-cells, natural killer cells (NK cells), and NK-T cells. Pre-clinical models have shown that an ADC combining a MUC-1 targeting antibody with the staphylococcal enterotoxin A (SEA) has activity against cholangiocarcinoma cell lines and that this activity can be augmented by LAK cells.
Additional studies of CAR-T cells in CCA have been conducted. One pre-clinical study evaluating a MUC-1 CAR-T cellular therapy in a CCA cell line demonstrated significant upregulation in cytokine production of IFN-γ and granzyme B when compared to un-transduced T-cells [59].
Clinical activity of cellular therapies in CCA has also been demonstrated. In one report, an EGFR-binding and CD133-restricted CAR-T combination was shown to provide 8.5 months of partial response in a patient with refractory CCA [60].

2.14. Cancer Vaccines

Cancer vaccines are currently under development in a multitude of solid tumors, including hepatobiliary malignancies. Several different approaches to utilizing cancer vaccines in CCA have been pursued, including mRNA-based technologies and personalized cancer vaccines. Huang et al. conducted a retrospective study that characterized the immune infiltrative potential of various antigens associated with CCA [61]. In their study, it was found that CD247, FCGR1A, and TRRAP were three antigens with expression patterns correlating with superior infiltration of T-cells and a subsequent increase in tumor inflammation of immune cells. These antigens represent promising targets for future CCA-directed vaccines.

3. Discussion

Cholangiocarcinoma is often diagnosed at late stages and is associated with an overall poor prognosis. Historically, these cancers have been very difficult to treat with systemic chemotherapy, and overall survival in patients with metastatic disease has been less than a year. The advent of whole exome sequencing has ushered in an era of targeted therapies for a multitude of solid tumor malignancies. Therapies targeting FGFR and IDH-1 have gained FDA approval after progression on front-line therapies for patients with cholangiocarcinoma. Additionally, less common driver mutations, such as BRAF and NTRK, have been investigated and may provide clinical benefit in a certain subset of patients. These mutations are very infrequently mutated, and prospective data on their usage in cholangiocarcinoma are limited.
The incorporation of immune checkpoint inhibitors into the treatment paradigm for cholangiocarcinoma has become the standard of care, with further studies showing clinical benefit in patients with MSI-H tumors. Despite these successes, the vast majority of patients do not derive a clinical benefit from immune checkpoint inhibitors. A significant number of patients with cholangiocarcinoma have either primary or acquired resistance to ICI therapies. Novel strategies have been explored to engage other components of the immune system to overcome this resistance. Adoptive cellular therapies, including invariant-NK cells, CAR-T, and cancer vaccines, have shown early promise; however, they are currently in the early clinical stage of development.

Author Contributions

Conceptualization, M.J.H., K.A. and K.D.; methodology M.J.H., K.A. and K.D.; formal analysis, M.J.H., K.A., K.D., G.S. and K.B.; investigation, M.J.H., K.A., K.D., G.S. and K.B.; data curation; M.J.H., K.A., K.D., G.S. and K.B.; writing—original draft preparation, M.J.H., K.D., K.A., K.B. and G.S.; writing—review and editing, M.J.H., K.D., K.A., K.B. and G.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 2023, 73, 17–48. [Google Scholar] [CrossRef] [PubMed]
  2. Valle, J.W.; Lamarca, A.; Goyal, L.; Barriuso, J.; Zhu, A.X. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov. 2017, 7, 943–962. [Google Scholar] [CrossRef] [PubMed]
  3. Duffy, A.; Capanu, M.; Abou-Alfa, G.; Huitzil, D.; Jarnagin, W.; Fong, Y.; D’Angelica, M.; DeMatteo, R.; Blumgart, L.; O’Reilly, E. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J. Surg. Oncol. 2008, 98, 485–489. [Google Scholar] [CrossRef] [PubMed]
  4. Nagino, M.; Ebata, T.; Yokoyama, Y.; Igami, T.; Sugawara, G.; Takahashi, Y.; Nimura, Y. Evolution of surgical treatment for perihilar cholangiocarcinoma: A single-center 34-year review of 574 consecutive resections. Ann. Surg. 2013, 258, 129–140. [Google Scholar] [CrossRef] [PubMed]
  5. Primrose, J.N.; Fox, R.P.; Palmer, D.H.; Malik, H.Z.; Prasad, R.; Mirza, D.; Anthony, A.; Corrie, P.; Falk, S.; Finch-Jones, M.; et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019, 20, 663–673. [Google Scholar] [CrossRef] [PubMed]
  6. Takada, T.; Amano, H.; Yasuda, H.; Nimura, Y.; Matsushiro, T.; Nakayama, T. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002, 95, 1685–1695. [Google Scholar] [PubMed]
  7. Horgan, A.M.; Amir, E.; Walter, T.; Knox, J.J. Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta-analysis. J. Clin. Oncol. 2012, 30, 1934–1940. [Google Scholar] [CrossRef] [PubMed]
  8. Rangarajan, K.; Simmons, G.; Manas, D.; Malik, H.; Hamady, Z.Z. Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: A systematic review and meta-analysis. Eur. J. Surg. Oncol. 2020, 46 Pt A, 684–693. [Google Scholar] [CrossRef]
  9. Valle, J.; Wasan, H.; Palmer, D.H.; Cunningham, D.; Anthoney, A.; Maraveyas, A.; Madhusudan, S.; Iveson, T.; Hughes, S.; Pereira, S.P.; et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 2010, 362, 1273–1281. [Google Scholar] [CrossRef]
  10. Oh, D.-Y.; Lee, K.-H.; Lee, D.-W.; Yoon, J.; Kim, T.-Y.; Bang, J.-H.; Nam, A.-R.; Oh, K.-S.; Kim, J.-M.; Lee, Y.; et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: An open-label, single-centre, phase 2 study. Lancet Gastroenterol. Hepatol. 2022, 7, 522–532. [Google Scholar] [CrossRef]
  11. Farshidfar, F.; Zheng, S.; Gingras, M.-C.; Newton, Y.; Shih, J.; Robertson, A.G.; Hinoue, T.; Hoadley, K.A.; Gibb, E.A.; Roszik, J.; et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell. Rep. 2017, 18, 2780–2794. [Google Scholar] [CrossRef] [PubMed]
  12. Mody, K.; Jain, P.; El-Refai, S.M.; Azad, N.S.; Zabransky, D.J.; Baretti, M.; Shroff, R.T.; Kelley, R.K.; El-Khouiery, A.B.; Hockenberry, A.J.; et al. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO Precis. Oncol. 2022, 6, e2100510. [Google Scholar] [CrossRef] [PubMed]
  13. Subbiah, V.; Lassen, U.; Élez, E.; Italiano, A.; Curigliano, G.; Javle, M.; Wainberg, Z.A. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020, 21, 1234–1243. [Google Scholar] [CrossRef] [PubMed]
  14. Adashek, J.J.; Menta, A.K.; Reddy, N.K.; Desai, A.P.; Roszik, J.; Subbiah, V. Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors. Mol. Cancer Ther. 2022, 21, 871–878. [Google Scholar] [CrossRef] [PubMed]
  15. Shi, K.; Wang, G.; Pei, J.; Zhang, J.; Wang, J.; Ouyang, L.; Wang, Y.; Li, W. Emerging strategies to overcome resistance to third-generation EGFR inhibitors. J. Hematol Oncol. 2022, 15, 94. [Google Scholar] [CrossRef] [PubMed]
  16. Sohal, D.P.S.; Mykulowycz, K.; Uehara, T.; Teitelbaum, U.R.; Damjanov, N.; Giantonio, B.J.; Carberry, M.; Wissel, P.; Jacobs-Small, M.; O’Dwyer, P.J.; et al. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann. Oncol. 2013, 24, 3061–3065. [Google Scholar] [CrossRef] [PubMed]
  17. Philip, P.A.; Mahoney, M.R.; Allmer, C.; Thomas, J.; Pitot, H.C.; Kim, G.; Donehower, R.C.; Fitch, T.; Picus, J.; Erlichman, C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 2005, 23, 6657–6663. [Google Scholar] [CrossRef] [PubMed]
  18. Malka, D.; Cervera, P.; Foulon, S.; Trarbach, T.; de la Fouchardière, C.; Boucher, E.; Fartoux, L.; Faivre, S.; Blanc, J.-F.; Viret, F.; et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): A randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014, 15, 819–828. [Google Scholar] [CrossRef]
  19. Lee, J.; Park, S.H.; Chang, H.M.; Kim, J.S.; Choi, H.J.; Lee, M.A.; Jang, J.S.; Jeung, H.C.; Kang, J.H.; Lee, H.W.; et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012, 13, 181–188. [Google Scholar] [CrossRef]
  20. Turner, N.; Grose, R. Fibroblast growth factor signalling: From development to cancer. Nat. Rev. Cancer 2010, 10, 116–129. [Google Scholar] [CrossRef]
  21. Ross, J.S.; Wang, K.; Gay, L.; Al-Rohil, R.; Rand, J.V.; Jones, D.M.; Lee, H.J.; Sheehan, C.E.; Otto, G.A.; Palmer, G.; et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 2014, 19, 235–242. [Google Scholar] [CrossRef] [PubMed]
  22. Graham, R.P.; Fritcher, E.G.B.; Pestova, E.; Schulz, J.; Sitailo, L.A.; Vasmatzis, G.; Murphy, S.J.; McWilliams, R.R.; Hart, S.N.; Halling, K.C.; et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum. Pathol. 2014, 45, 1630–1638. [Google Scholar] [CrossRef] [PubMed]
  23. Churi, C.R.; Shroff, R.; Wang, Y.; Rashid, A.; Kang, H.C.; Weatherly, J.; Zuo, M.; Zinner, R.; Hong, D.; Meric-Bernstam, F.; et al. Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications. PLoS ONE 2014, 9, e115383. [Google Scholar] [CrossRef] [PubMed]
  24. Abou-Alfa, G.K.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A.S.; Borad, M.J.; Gallinson, D.; Murphy, A.G.; et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol. 2020, 21, 671–684. [Google Scholar] [CrossRef] [PubMed]
  25. Bekaii-Saab, T.S.; Valle, J.W.; Van Cutsem, E.; Rimassa, L.; Furuse, J.; Ioka, T.; Melisi, D.; Macarulla, T.; Bridgewater, J.; Wasan, H.; et al. FIGHT-302: First-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 2020, 16, 2385–2399. [Google Scholar] [CrossRef] [PubMed]
  26. Javle, M.; Roychowdhury, S.; Kelley, R.K.; Sadeghi, S.; Macarulla, T.; Weiss, K.H.; Waldschmidt, D.-T.; Goyal, L.; Borbath, I.; El-Khoueiry, A.; et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol. Hepatol. 2021, 6, 803–815. [Google Scholar] [CrossRef] [PubMed]
  27. Goyal, L.; Meric-Bernstam, F.; Hollebecque, A.; Valle, J.W.; Morizane, C.; Karasic, T.B.; Abrams, T.A.; Furuse, J.; Kelley, R.K.; Cassier, P.A.; et al. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N. Engl. J. Med. 2023, 388, 228–239. [Google Scholar] [CrossRef] [PubMed]
  28. Abou-Alfa, G.K.; Macarulla, T.; Javle, M.M.; Kelley, R.K.; Lubner, S.J.; Adeva, J.; Cleary, J.M.; Catenacci, D.V.; Borad, M.J.; Bridgewater, J.; et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020, 21, 796–807. [Google Scholar] [CrossRef]
  29. Boscoe, A.N.; Rolland, C.; Kelley, R.K. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: A systematic literature review. J. Gastrointest Oncol. 2019, 10, 751–765. [Google Scholar] [CrossRef]
  30. de Botton, S.; Fenaux, P.; Yee, K.; Récher, C.; Wei, A.H.; Montesinos, P.; Cortes, J. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023, 7, 3117–3127. [Google Scholar] [CrossRef]
  31. Wang, Y.; Wild, A.T.; Turcan, S.; Wu, W.H.; Sigel, C.; Klimstra, D.S.; Ma, X.; Gong, Y.; Holland, E.C.; Huse, J.T.; et al. Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. Sci. Adv. 2020, 6, eaaz3221. [Google Scholar] [CrossRef]
  32. Galogre, M.; Rodin, D.; Pyatnitskiy, M.; Mackelprang, M.; Koman, I. A review of HER2 overexpression and somatic mutations in cancers. Crit. Rev. Oncol. Hematol. 2023, 186, 103997. [Google Scholar] [CrossRef] [PubMed]
  33. Roa, I.; de Toro, G.; Schalper, K.; de Aretxabala, X.; Churi, C.; Javle, M. Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer. Gastrointest Cancer Res. 2014, 7, 42–48. [Google Scholar] [PubMed]
  34. Kim, H.J.; Yoo, T.W.; Park, D.I.; Park, J.H.; Cho, Y.K.; Sohn, C.I.; Sohn, J.H. Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: Its prognostic implication in node-positive patients. Ann. Oncol. 2007, 18, 892–897. [Google Scholar] [CrossRef] [PubMed]
  35. Galdy, S.; Lamarca, A.; McNamara, M.G.; Hubner, R.A.; Cella, C.A.; Fazio, N.; Valle, J.W. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: A potential therapeutic target? Cancer Metastasis Rev. 2017, 36, 141–157. [Google Scholar] [CrossRef] [PubMed]
  36. May, M.; Raufi, A.G.; Sadeghi, S.; Chen, K.; Iuga, A.; Sun, Y.; Ahmed, F.; Bates, S.; Manji, G.A. Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature. Oncologist 2021, 26, 640–646. [Google Scholar] [CrossRef] [PubMed]
  37. Javle, M.; Borad, M.J.; Azad, N.S.; Kurzrock, R.; Abou-Alfa, G.K.; George, B.; Hainsworth, J.; Meric-Bernstam, F.; Swanton, C.; Sweeney, C.J.; et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021, 22, 1290–1300. [Google Scholar] [CrossRef] [PubMed]
  38. Meric-Bernstam, F.; Beeram, M.; Hamilton, E.; Oh, D.-Y.; Hanna, D.L.; Kang, Y.-K.; Elimova, E.; Chaves, J.; Goodwin, R.; Lee, J.; et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: A phase 1, dose-escalation and expansion study. Lancet Oncol. 2022, 23, 1558–1570. [Google Scholar] [CrossRef] [PubMed]
  39. Ohba, A.; Morizane, C.; Ueno, M.; Kobayashi, S.; Kawamoto, Y.; Komatsu, Y.; Ikeda, M.; Sasaki, M.; Okano, N.; Furuse, J.; et al. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncol. 2022, 18, 2351–2360. [Google Scholar] [CrossRef]
  40. Li, K.; Luo, H.; Huang, L.; Luo, H.; Zhu, X. Microsatellite instability: A review of what the oncologist should know. Cancer Cell. Int. 2020, 20, 16. [Google Scholar] [CrossRef]
  41. Williams, A.S.; Huang, W.-Y. The analysis of microsatellite instability in extracolonic gastrointestinal malignancy. Pathology 2013, 45, 540–552. [Google Scholar] [CrossRef]
  42. Marabelle, A.; Le, D.T.; Ascierto, P.A.; Di Giacomo, A.M.; De Jesus-Acosta, A.; Delord, J.P. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J. Clin. Oncol. 2020, 38, 1. [Google Scholar] [CrossRef] [PubMed]
  43. Marabelle, A.; Fakih, M.; Lopez, J.; Shah, M.; Shapira-Frommer, R.; Nakagawa, K.; Chung, H.C.; Kindler, H.L.; Lopez-Martin, J.A.; Miller, W.H., Jr.; et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020, 21, 1353–1365. [Google Scholar] [CrossRef] [PubMed]
  44. Perez-Fidalgo, J.A.; Martinelli, E. Lenvatinib plus pembrolizumab a new effective combination of targeted agents. ESMO Open 2023, 8, 101157. [Google Scholar] [CrossRef] [PubMed]
  45. Kim, R.D.; Chung, V.; Alese, O.B.; El-Rayes, B.F.; Li, D.; Al-Toubah, T.E.; Schell, M.J.; Zhou, J.-M.; Mahipal, A.; Kim, B.H.; et al. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol. 2020, 6, 888–894. [Google Scholar] [CrossRef] [PubMed]
  46. Manea, C.A.; Badiu, D.C.; Ploscaru, I.C.; Zgura, A.; Bacinschi, X.; Smarandache, C.G.; Serban, D.; Popescu, C.G.; Grigorean, V.T.; Botnarciuc, V. A review of NTRK fusions in cancer. Ann. Med. Surg. 2022, 79, 103893. [Google Scholar] [CrossRef] [PubMed]
  47. Drilon, A.; Laetsch, T.W.; Kummar, S.; DuBois, S.G.; Lassen, U.N.; Demetri, G.D.; Hyman, D.M. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N. Engl. J. Med. 2018, 378, 731–739. [Google Scholar] [CrossRef] [PubMed]
  48. Doebele, R.C.; Drilon, A.; Paz-Ares, L.; Siena, S.; Shaw, A.T.; Farago, A.F.; Blakely, C.M.; Seto, T.; Cho, B.C.; Tosi, D.; et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020, 21, 271–282. [Google Scholar] [CrossRef]
  49. Moehler, M.; Maderer, A.; Schimanski, C.; Kanzler, S.; Denzer, U.; Kolligs, F.; Ebert, M.; Distelrath, A.; Geissler, M.; Trojan, J.; et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. Eur. J. Cancer 2014, 50, 3125–3135. [Google Scholar] [CrossRef]
  50. Demols, A.; Borbath, I.; Eynde, M.V.D.; Houbiers, G.; Peeters, M.; Marechal, R.; Delaunoit, T.; Goemine, J.-C.; Laurent, S.; Holbrechts, S.; et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. Ann. Oncol. 2020, 31, 1169–1177. [Google Scholar] [CrossRef]
  51. Sun, W.; Patel, A.; Normolle, D.; Patel, K.; Ohr, J.; Lee, J.J.; Drummond, S. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer 2019, 125, 902–909. [Google Scholar] [CrossRef]
  52. Farha, N.; Dima, D.; Ullah, F.; Kamath, S. Precision Oncology Targets in Biliary Tract Cancer. Cancers 2023, 15, 2105. [Google Scholar] [CrossRef] [PubMed]
  53. Thein, K.Z.; Velcheti, V.; Mooers, B.H.; Wu, J.; Subbiah, V. Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer 2021, 7, 1074–1088. [Google Scholar] [CrossRef] [PubMed]
  54. Subbiah, V.; Wolf, J.; Konda, B.; Kang, H.; Spira, A.; Weiss, J.; Drilon, A. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): A phase 1/2, open-label, basket trial. Lancet Oncol. 2022, 23, 1261–1273. [Google Scholar] [CrossRef] [PubMed]
  55. Kuwatani, M.; Sakamoto, N. Promising Highly Targeted Therapies for Cholangiocarcinoma: A Review and Future Perspectives. Cancers 2023, 15, 3686. [Google Scholar] [CrossRef] [PubMed]
  56. Yokota, K.; Serada, S.; Tsujii, S.; Toya, K.; Takahashi, T.; Matsunaga, T.; Fujimoto, M.; Uemura, S.; Namikawa, T.; Murakami, I.; et al. Anti-Glypican-1 Antibody-drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1-Positive Cholangiocarcinoma. Mol. Cancer Ther. 2021, 20, 1713–1722. [Google Scholar] [CrossRef] [PubMed]
  57. Zhu, B.; Wang, X.; Shimura, T.; Huang, A.C.; Kong, N.; Dai, Y.; Fang, J.; Guo, P.; Ying, J.-E. Development of potent antibody drug conjugates against ICAM1(+) cancer cells in preclinical models of cholangiocarcinoma. NPJ Precis Oncol. 2023, 7, 93. [Google Scholar] [CrossRef] [PubMed]
  58. Danese, E.; Ruzzenente, A.; Montagnana, M.; Lievens, P.M.-J. Current and future roles of mucins in cholangiocarcinoma-recent evidences for a possible interplay with bile acids. Ann. Transl. Med. 2018, 6, 333. [Google Scholar] [CrossRef] [PubMed]
  59. Supimon, K.; Sangsuwannukul, T.; Sujjitjoon, J.; Phanthaphol, N.; Chieochansin, T.; Poungvarin, N.; Wongkham, S.; Junking, M.; Yenchitsomanus, P.-T. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma. Sci. Rep. 2021, 11, 6276. [Google Scholar] [CrossRef]
  60. Feng, K.-C.; Guo, Y.-L.; Liu, Y.; Dai, H.-R.; Wang, Y.; Lv, H.-Y.; Huang, J.-H.; Yang, Q.-M.; Han, W.-D. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J. Hematol. Oncol. 2017, 10, 4. [Google Scholar] [CrossRef]
  61. Huang, X.; Tang, T.; Zhang, G.; Liang, T. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Mol. Cancer 2021, 20, 50. [Google Scholar] [CrossRef]
Ijms 25 00543 g001
Figure 1. Overview of current therapeutic targets in cholangiocarcinoma.
Figure 1. Overview of current therapeutic targets in cholangiocarcinoma.
Ijms 25 00543 g001
Table 1. Clinical trials by targeted agent.
Table 1. Clinical trials by targeted agent.
NTC NumberPhaseDiseaseInterventionOutcomeStatus
NCT05876754IIIbUnresectable and/or metastatic CCAivosidenib (IDH1)AEs, SAEs, QT prolonging events, ECOG, lab abnormalities, changes from baseline of labs and vitalsEnrolling
NCT03603834IIResectable CCAneoadjuvant mFOLFOXIRIORREnrolling
NCT04989218I and IIResectable and high-risk feature ICCdurvalumab/MEDI4736 (anti-PD-L1), tremelimumab (CTLA-4), GemCisORREnrolling
NCT05348811IIUnresectable and/or metastatic ICCGEMOX hepatic arterial infusion chemotherapy (HAIC), donafenib (small molecule multikinase inhibitor), sintilimab (anti-PD-1)ORR and hORREnrolling
NCT03820310IITreated with radical resection completely ICCAutologous Tcm cellular immunotherapy and traditional therapyPFS, 2-year survivalEnrolling
NCT02773485IIIUnresectable and nonmetastatic CCAHigh-dose radiation with systemic themotherapyOSEnrolling
NCT03656536IIIUnresectable and/or metastatic CCApemigatinib (FGFR-inhibitor) vs. GemCisPFSEnrolling
NCT05655949IIUnresectable and/or metastatic IHCY-90 SIRT with durvalumab (anti-PD-L1), GemCisPFS, grade 3 or higher AEEnrolling
NCT05532059IIUnresectable and/or metastatic CCAlenvatinib (VEGFR1-3), tislelizumab (anti-PD-1), GemCisORREnrolling
NCT05400902IIUnresectable ICC with at least one assessable intrahepatic lesionFOLFOX6 hepatic arterial infusion chemotherapy, sintilimab (anti-PD-1), bevacizumab (VEGF-i)ORREnrolling
NCT05290116IIUnresectable ICC with at least one assessable intrahepatic lesionFOLFOX6 hepatic arterial infusion chemotherapy, tislelizumab (anti-PD-1), apatinib (TKI)ORREnrolling
NCT05251662IIUnresectable CCAsintilimab (anti-PD-1), GEMOX, IBI305 (bevacizumab biosimilar)ORREnrolling
NCT05430698IIResectable perihilar CCA with positive metastatic LNsAdjuvant PD-1 antibody, GEMOX12 mo relapse-free survival rateEnrolling
NCT04295317IIResectable ICCcamrelizumab (anti-PD-1) and capecitabineRecurrence-free survivalEnrolling
NCT05823311IIIUnresectable and/or metastatic CCAlenvatinib (VEGFR1-3), tislelizumab (anti-PD-1), GemCisORREnrolling
NCT04954781IIUnresectable or metastatic CCATranscatheter arterial chemoembolization (TACE) tislelizumab (anti-PD-1)ORREnrolling
NCT05010668IIUnresectable and/or metastatic ICCCryoablation, sintilimab (anti-PD-1), lenvatinib (VEGFR1-3)ORREnrolling
NCT04299581IIUnresectable and/or metastatic ICCCryoablation and Camrelizumab (Anti-PD-1)ORREnrolling
NCT04891289IIUnresectable and liver metastasis ICCGemcitabine, oxaliplatin, floxuridine, and dexamethasone pumpPFSEnrolling
NCT03633773I and IINonsurgical candidate, ICCMUC-1 CART cell immunotherapyDCREnrolling
NCT05557578IIResectable ICC and high-risk recurrenceNeoadjuvant tislelizumab (anti-PD-1) and GEMOXORR, R0 resection rateEnrolling
NCT04961970IIIUnresectable or local metastatic ICCFOLFOX hepatic arterial infusion chemotherapy vs. GemCisOSEnrolling
NCT04782804I and IIPost R0 resection ICCAdjuvant tislelizumab (anti-PD-1) and capecitabineRFSEnrolling
NCT05174650IINon-resectable ICC and FGFR2+atezolizumab (anti-PD-L1) and derazantinib (FGFR1–3 kinase inhibitor)ORREnrolling
NCT04454905IIUnresectable and/or metastatic ICCcamrelizumab (anti-PD-1) and apatinib (TKI)PFSEnrolling
NCT04238637IILocally advanced OR limited metasized intrahepatic BTCY-90 SIRT with durvalumab (anti-PD-L1) or tremelimumab (CTLA-4i)ORREnrolling
NCT05010681IIUnresectable and/or metastatic ICC or HCCsintilimab (anti-PD-1), lenvatinib (VEGFR1-3)ORREnrolling
NCT05678270IIUnresectable, recurrent or metastatic ICC and FGFR2+gunagratinib (FGFR-inhibitor)ORREnrolling
NCT05921760I, IIUnresectable and/or metastatic CCA, IDH1+ivosidenib, nivolumab (anti-PD1), ipilimumab (CTLA-4i)Dose-limiting toxicities (DLT), recommended combination dose (RDC), ORR, AEs, SAEsEnrolling
NCT04353375IIUnresectable and/or metastatic ICC, FGFR2+HMPL-453 tartrate (FGFR1, FGFR2, FGFR3 antagonist)ORREnrolling
NCT05835245IIUnresectable and/or metastatic ICCCryoablation with sintilimab (anti-PD-1), lenvatinib (VEGFR1-3)ORREnrolling
NCT05978609IIUnresectable and/or metastatic CCACandonilimab (PD-1/CTLA-4), GemCisORREnrolling
NCT04951141IUnresectable liver tumor, GPC3+anti-GPC3 CAR-T cellsAEsEnrolling
NCT04708067IUnresectable and/or metastatic ICCbintrafusp alfa and hypofractionated radiation therapyAEsEnrolling
NCT05672537IIResectable ICCNeoadjuvant durvalumab (anti-PD-L1), surgery, GemCisRFSEnrolling
NCT05239169IIUnresectable and/or metastatic BTCdurvalumab (anti-PD-L1), tremelimumab (CTLA-4), capecitabineRFSEnrolling
NCT05223816IIa/IIbUnresectable and/or metastatic ICCVG-161 (IL-12, IL-15, PD-L1), nivolumab (anti-PD1)OS, ORR, PFSEnrolling
NCT05220722I, IIUnresectable and/or metastatic ICCSD-101 (TLR 9 agonist), pembrolizumab (anti-PD-1), nivolumab (anti-PD1), ipilimumab (CTLA-4i)Safety, maximum tolerable dose (MTD), ORREnrolling
NCT06037980II, IIIResectable BTC at high risk for recurrenceGemCis, nabpaclitaxel vs. upfront surgeryPFSEnrolling
NCT03779035IIIBTC after curative resectionAdjuvant GemCis vs. capecitabineDFSEnrolling
NCT04634058IIUnresectable and metastatic ICCPD-L1 and CTLA-4ORREnrolling
NCT03364530IINonmetastatic unresectable ICCHepatic intra-aterial Gemcitabine-OxaliplatinORREnrolling
NCT04298021IIUnresectable and/or recurrent BTCAZD6738 (ATR Kinase-i), durvalumab (anti-PD-L1), olaparib (PARP-i)DCREnrolling
NCT04298008IIUnresectable and/or recurrent BTCAZD6738 (ATR Kinase-i) and durvalumab (anti-PD-L1)DCREnrolling
NCT05727176IIUnresectable and/or metastatic CCA, FGFR2+Futibatinib (FGFR1–4 inhibitor)ORREnrolling
NCT06081322IAdvanced cholangiocarcinoma177Lu-EB-FAPI PRRT (FAP inhibitor molecule)Hematoxicity, ORR, hepatotoxicity, renal toxicityEnrolling
NCT04413734IIUnresectable and/or metastatic BTCtriprilumab (anti-PD-1), GemCisPFSEnrolling
NCT04251715IIdUnresectable ICCmFOLFIRINOX, hepatic arterial infusion of floxuridine, dexamethasone, and systemic mFOLFIRIIncidence of abnormal liver function, DCREnrolling
NCT05568680IRecurrent or relapsed advanced mesothelial CCASynKIR-110 (anti-mesothelin)Safety and feasibilityEnrolling
NCT04565275I, IIUnresectable and/or metastatic CCA, FGFR+ICP-192 (pan-FGFR inhibitor)AEs, MTD, OBD, RP2D, ORREnrolling
NCT03991832IIAdenocarcinoma BTC, IDH+olaparib (PARP-i), durvalumab (anti-PD-L1)ORR, DCREnrolling
NCT04264260IIICCcolchicineOSEnrolling
NCT04669496II, IIIResectable ICC and high-risk recurrenceneoadjuvant toripalimab (anti-PD-1), lenvatinib (VEGF1-3), GEMOXEvent free survivalEnrolling
NCT05286814IIUnresectable and/or metastatic CCAM9241 (IL-12 heterodimers) hepatic artery infusion pump and systemic chemotherapy, dexamethasoneORREnrolling
NCT03801083IIUnresectable, recurrent, or metastatic BTCAutologous tumor-infiltrating lymphocytes (TIL)ORREnrolling
NCT05242822IAdvanced stage CCA, FGFR2+ and/or FGFR3+KIN-3248 (small molecule pan-FGFRi)DLT, AEs, ORR, DCR, duration of response, PFSEnrolling
NCT05724563IIUnresectable and/or metastatic BTCdomvanalimab (anti-TIGIT), zimberelimab (anti-PD-1)ORREnrolling
NCT05913661IIUnresectable and/or metastatic ICCpemigatinib (FGFR-inhibitor) and anti-PD-1ORREnrolling
NCT04645160I, IIUnresectable BTCtivozanib (VEGF-i)ORR, RP2DEnrolling
NCT04068194I, IIUnresectable and/or metastatic ICCpeposertib (DNA-PK-i), avelumab (anti-PD-L1), RTMTD, ORREnrolling
NCT05565794IIcuratively treatable localized ICC, FGFR2+pemigatinib (FGFR-inhibitor)ORREnrolling
NCT04526106I, IIUnresectable and/or metastatic CCARLY-4008 (FGFR2-i)MTD, AEs, SAEs, ORREnrolling
NCT05620498IIPotentially resectable ICC and GBCtislelizumab (anti-PD-1), lenvatinib lenvatinib (VEGFR1-3), GEMOXORREnrolling
NCT05506943II, IIIUnresectable, metastatic, or recurrent BTCCTX-009 (Delta-like ligand 4/Notch-1 (DLL4) and VEGF-A inhibitor)BOREnrolling
NCT03942328I, IIUnresectable ICCintra-tumoral injection of autologous dendritic cells and prevnar vaccine after EBRT, atezolizumab (anti-PD-L1), bevacizumab (VEGF-i)incidence of significant toxicity, PFSEnrolling
NCT05564403IIUnresectable or recurrent BTC, RAS/RAF/MEK/ERK+binimetinib (MEK-i), FOLFOXOSEnrolling
NCT05211323IIUnresectable or metastatic cHCC-CCatezolizumab (anti-PD-L1), bevacizumab (VEGF-i), GemCisPFSEnrolling
NCT03212274IIBTC, IDH1/2+olaparib (PARP-i),ORREnrolling
NCT05805956I, IIUnresectable and/or metastatic BTC, HER2+IMM2902 (anti-CD47/anti-HER2 bispecific antibody)MTD, RP2D, AEs, ORR, DOR, DCR, PFSEnrolling
NCT05411133IUnresectable and/or metastatic BTC, CDH17+ARB202 (CDH17-CD3 bispecific T-cell engager antibody)SAEsEnrolling
NCT04801095IUnresectable and/or metastatic BTCWM-S1-030 (inhibitor for mtRTK)DLT, AEs, SAEsEnrolling
NCT04430738I, IIUnresectable and/or metastatic BTCtucatinib (HER2 tyrosine kinase inhibitor), trastazumab (anti-EGFR), oxaliplatin-based chemotherapy, pembrolizumab (anti-PD-1)DLT; AEs; incidence of lab abnormalities, DLTs, dose alterationsEnrolling
NCT05285358IBTC with peritoneal metastasispressurized intraperitoneal aerosolized nab-paclitaxel, GemCisAEsEnrolling
NCT06010862IUnresectable and/or metastatic BTC, CEA+CEA-targeted CAR-TAEs, MTDEnrolling
NCT05185947IIBTC with peritoneal metastasisintravenous and intraperitoneal paclitaxel, nilotinib (transduction inhibitor of BCR-ABL, c-kit and PDGF)OS, PFS, safety, tolerability, QOL, ORREnrolling
NCT05991518I, IIUnresectable and/or metastatic BTC, HER2+IAH0968 (afucosylated anti-EGFR2), GemCIsAE, SAEs, DLT, ORREnrolling
NCT06126406IUnresectable and/or metastatic BTC, CEA+CEA-targeted CAR-TAEs, MTDEnrolling
NCT03907852I, IIBTC, MSLN+Gavocabtagene Autoleucel (anti-Mesothelin), fludarabine, cyclophosphamide, nivolumab (anti-PD1), ipilimumab (CTLA-4i)RP2D, ORR, DCREnrolling
NCT06043466IUnresectable and/or metastatic BTC, CEA+CEA-targeted CAR-TDLT, MTDEnrolling
NCT05277766IBTC with peritoneal metastasisintraperitoneal aerosolized nano liposomal irinotecanMTDEnrolling
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Hadfield, M.J.; DeCarli, K.; Bash, K.; Sun, G.; Almhanna, K. Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review. Int. J. Mol. Sci. 2024, 25, 543. https://doi.org/10.3390/ijms25010543

AMA Style

Hadfield MJ, DeCarli K, Bash K, Sun G, Almhanna K. Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review. International Journal of Molecular Sciences. 2024; 25(1):543. https://doi.org/10.3390/ijms25010543

Chicago/Turabian Style

Hadfield, Matthew J., Kathryn DeCarli, Kinan Bash, Grace Sun, and Khaldoun Almhanna. 2024. "Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review" International Journal of Molecular Sciences 25, no. 1: 543. https://doi.org/10.3390/ijms25010543

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop